Bioceres Crop Solutions Corp. (BIOX) Key Metrics
BIOX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $17.6M
- Enterprise value
- $249.6M
- P/E (TTM)
- — 10-yr median 65.7
- Forward P/E
- 15.0
- PEG ratio
- 1.95
- Price / sales
- 0.1 10-yr median 1.5
- Price / book
- 0.6 10-yr median 3.4
- EV / EBITDA
- 18.0 10-yr median 15.0
- Dividend yield
- —
- Beta
- 0.47
BIOX key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsBIOX valuation Price multiples at each fiscal year-end price.
Price / sales−89.0%
0.1
FY2026 · hover or tap a bar for each year
FY2017FY2026
Price / book−47.0%
0.6
FY2026 · hover or tap a bar for each year
FY2017FY2026
BIOX returns How much profit the business earns on the capital it uses.
Return on equity−133.4 pts
−152.6%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on invested capital+0.1 pts
0.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets−30.4 pts
−37.3%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover−6.6%
0.39
FY2026 · hover or tap a bar for each year
FY2017FY2026
BIOX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−29.1%
$3.74
FY2026 · hover or tap a bar for each year
FY2017FY2026
Earnings per share
−$3.62
FY2026 · hover or tap a bar for each year
FY2017FY2026
Book value per share−85.2%
$0.61
FY2026 · hover or tap a bar for each year
FY2017FY2026
Shares outstanding+0.6%
63.6M
FY2026 · hover or tap a bar for each year
FY2017FY2026
BIOX financial health Debt, liquidity and how easily interest is covered.
Debt / equity+475.4%
6.06
FY2026 · hover or tap a bar for each year
FY2017FY2026
Net debt−$17.3M
$224.6M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio−11.6%
0.81
FY2026 · hover or tap a bar for each year
FY2017FY2026
Interest coverage
0.0
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets+38.7%
0.50
FY2026 · hover or tap a bar for each year
FY2017FY2026
BIOX efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+7 days
222 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days of inventory−32 days
161 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days payables outstanding−50 days
175 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Cash conversion cycle+25 days
207 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
BIOX valuation history
Fiscal year-endToday10-year median
BIOX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BIOX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BIOX cash returned to shareholders
DividendsBuybacksFree cash flow
BIOX price vs earnings per share
Share price at year-endEPS (right axis)
BIOX key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $22.3M | $282.5M | $711.7M | $844.2M | $580.0M | $551.0M | $220.7M | $161.5M | $272.3M | — |
| Enterprise value | $246.9M | $524.4M | $926.4M | $1.04B | $711.1M | $678.8M | $314.5M | $261.3M | $361.1M | — |
| P/E ratio | — | — | 219.4 | 45.0 | — | — | 65.7 | — | — | — |
| Price / sales | 0.1 | 0.8 | 1.5 | 2.0 | 1.8 | 2.7 | 1.3 | 1.0 | 2.0 | — |
| Price / book | 0.6 | 1.1 | 2.3 | 2.8 | 4.5 | 8.1 | 4.9 | 3.4 | 8.2 | — |
| Price / free cash flow | — | 8.0 | 37.6 | — | — | — | 45.8 | 6.2 | 21.5 | — |
| Price / operating cash flow | — | 5.7 | 17.1 | 326.1 | — | — | 23.7 | 5.4 | 14.8 | — |
| EV / sales | 1.0 | 1.6 | 2.0 | 2.5 | 2.2 | 3.3 | 1.8 | 1.6 | 2.7 | — |
| EV / EBITDA | — | — | 16.7 | 14.4 | 14.8 | 15.5 | 10.3 | 15.1 | — | — |
| EV / free cash flow | — | 14.9 | 48.9 | — | — | — | 65.3 | 10.0 | 28.5 | — |
| Earnings yield | −1,034.6% | −19.6% | 0.5% | 2.2% | −1.2% | −1.2% | 1.5% | −11.4% | −4.1% | — |
| Free cash flow yield | — | 12.5% | 2.7% | −2.4% | −4.6% | −3.7% | 2.2% | 16.2% | 4.7% | — |
| Dividend yield | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | — |
| Shareholder yield (dividends + buybacks) | — | 0.3% | 0.1% | 0.4% | 0.5% | 0.8% | 0.0% | 0.0% | 0.0% | — |
| Share price at fiscal year-end | $0.35 | $4.47 | $11.21 | $13.36 | $13.71 | $14.05 | $6.06 | $5.30 | $9.69 | — |
| Per share | ||||||||||
| Revenue per share | $3.74 | $5.27 | $7.32 | $6.64 | $7.76 | $5.27 | $4.73 | $5.26 | $4.75 | $3.33 |
| Earnings per share | −$3.62 | −$0.88 | $0.05 | $0.30 | −$0.17 | −$0.18 | $0.09 | −$0.60 | −$0.39 | −$0.42 |
| Operating cash flow per share | — | $0.79 | $0.66 | $0.04 | −$0.41 | −$0.16 | $0.26 | $0.97 | $0.65 | $0.68 |
| Free cash flow per share | — | $0.56 | $0.30 | −$0.32 | −$0.63 | −$0.51 | $0.13 | $0.86 | $0.45 | $0.63 |
| Cash per share | $0.19 | $0.55 | $0.88 | $0.95 | $0.91 | $1.19 | $1.54 | $0.12 | $0.08 | $0.06 |
| Book value per share | $0.61 | $4.16 | $4.97 | $4.73 | $3.02 | $1.73 | $1.25 | $1.55 | $1.18 | $1.36 |
| Tangible book value per share | −$1.25 | −$0.48 | $0.41 | $0.20 | $0.35 | −$0.72 | −$0.42 | −$0.73 | −$0.28 | −$1.02 |
| Dividends per share | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.03 | $0.00 | $0.00 | $0.00 | $0.00 |
| Capex per share | — | $0.23 | $0.36 | $0.36 | $0.21 | $0.36 | $0.12 | $0.11 | $0.20 | $0.05 |
| Debt per share | $3.72 | $4.38 | $4.27 | $4.07 | $4.01 | $4.45 | $4.11 | $3.40 | $3.24 | $2.67 |
| Shares outstanding | 63.6M | 63.2M | 63.5M | 63.2M | 42.3M | 39.2M | 36.4M | 30.5M | 28.1M | 28.1M |
| Change in shares outstanding | +0.6% | −0.4% | +0.5% | +49.4% | +7.9% | +7.7% | +19.5% | +8.5% | 0.0% | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −152.6% | −19.2% | 1.1% | 8.8% | −7.4% | −12.1% | 7.2% | −45.7% | −30.9% | −30.8% |
| Return on invested capital (ROIC) | 0.0% | −0.1% | 5.4% | 14.4% | 8.8% | 11.5% | 18.0% | 18.8% | 10.6% | −0.5% |
| Return on assets (ROA) | −37.3% | −6.9% | 0.4% | 2.8% | −1.6% | −2.0% | 1.2% | −8.4% | −5.1% | −4.9% |
| Return on tangible assets | −65.2% | −11.8% | 0.6% | 3.5% | −1.8% | −2.3% | 1.4% | −10.6% | −7.1% | −6.8% |
| Free cash flow margin | — | 10.6% | 4.1% | −4.8% | −8.1% | −9.7% | 2.8% | 16.4% | 9.5% | 18.9% |
| Income quality (OCF / net income) | — | — | 12.86 | 0.14 | — | — | 2.77 | — | — | — |
| Financial health | ||||||||||
| Total debt | $236.8M | $276.6M | $270.9M | $257.4M | $169.8M | $174.6M | $149.8M | $103.6M | $91.0M | $75.0M |
| Cash & short-term investments | $12.2M | $34.7M | $56.2M | $60.1M | $38.6M | $46.8M | $56.0M | $3.8M | $2.2M | $1.7M |
| Net debt | $224.6M | $241.9M | $214.8M | $197.4M | $131.2M | $127.8M | $93.8M | $99.7M | $88.8M | $73.3M |
| Debt / equity | 6.06 | 1.05 | 0.86 | 0.86 | 1.33 | 2.58 | 3.29 | 2.19 | 2.75 | 1.96 |
| Debt / assets | 0.50 | 0.36 | 0.32 | 0.31 | 0.33 | 0.44 | 0.50 | 0.43 | 0.46 | 0.31 |
| Net debt / EBITDA | — | — | 3.87 | 2.73 | 2.74 | 2.92 | 3.07 | 5.77 | — | 18.80 |
| Current ratio | 0.81 | 0.91 | 1.24 | 1.33 | 1.34 | 1.26 | 1.26 | 0.84 | 0.72 | 1.26 |
| Quick ratio | 0.63 | 0.65 | 0.86 | 0.86 | 0.77 | 0.88 | 1.03 | 0.61 | 0.56 | 0.81 |
| Interest coverage | 0.0 | -0.0 | 1.7 | 2.3 | 2.2 | 1.8 | 2.0 | 1.5 | 1.0 | -0.0 |
| Working capital | −$51.8M | −$29.7M | $79.4M | $98.4M | $75.0M | $43.5M | $34.1M | −$18.2M | −$33.3M | $18.4M |
| Invested capital | $263.7M | $504.7M | $530.1M | $496.2M | $258.8M | $195.5M | $139.3M | $147.1M | $121.9M | $111.6M |
| Tangible asset value | −$54.2M | $1.9M | $62.3M | $44.5M | $45.5M | −$5.8M | −$811,483 | −$7.3M | −$8.0M | $12.6M |
| Net current asset value | −$192.0M | −$160.1M | −$92.5M | −$90.4M | −$62.2M | −$92.8M | −$72.8M | −$82.2M | −$78.2M | −$72.4M |
| Graham number | — | — | $2.39 | $5.62 | — | — | $1.61 | — | — | — |
| Graham net-net per share | −$4.53 | −$4.04 | −$3.46 | −$3.45 | −$3.83 | −$3.86 | −$2.96 | −$3.88 | −$3.83 | −$3.97 |
| Capital allocation | ||||||||||
| Dividends paid | — | $0 | $0 | $0 | $0 | $1.0M | $0 | $0 | $0 | $0 |
| Share buybacks (net) | — | $926,899 | $734,388 | $3.0M | $3.0M | $3.5M | $30,906 | $30,906 | $0 | $0 |
| Dividend payout ratio | — | — | 0.0% | 0.0% | — | — | 0.0% | — | — | — |
| Dividends + buybacks / free cash flow | — | 2.6% | 3.9% | — | — | — | 0.6% | 0.1% | 0.0% | 0.0% |
| Capex / revenue | — | 4.4% | 4.9% | 5.4% | 2.7% | 6.7% | 2.6% | 2.2% | 4.3% | 1.5% |
| Capex / operating cash flow | — | 29.3% | 54.6% | 871.6% | — | — | 48.3% | 11.6% | 31.0% | 7.3% |
| Capex / depreciation | — | 0.66 | 1.07 | 1.16 | 0.98 | 2.22 | 0.95 | 0.71 | 1.31 | 0.30 |
| Stock-based compensation / revenue | — | 1.3% | 3.0% | 0.8% | 0.4% | 0.8% | 2.0% | −0.1% | 0.0% | 0.1% |
| R&D / revenue | — | 4.5% | 3.7% | 3.7% | 2.1% | 2.7% | 2.4% | 2.3% | 3.0% | 4.2% |
| SG&A / revenue | — | 26.5% | 20.3% | 20.4% | 17.5% | 21.5% | 17.1% | 19.2% | 26.4% | 29.2% |
| Efficiency | ||||||||||
| Days sales outstanding | 222.1 | 215.6 | 157.6 | 136.4 | 126.3 | 156.3 | 145.1 | 134.3 | 137.2 | 162.3 |
| Days of inventory on hand | 160.5 | 192.3 | 171.9 | 203.5 | 171.2 | 148.3 | 114.7 | 98.9 | 120.0 | 191.1 |
| Days payables outstanding | 175.2 | 225.5 | 198.6 | 206.5 | 175.0 | 195.5 | 183.7 | 135.5 | 113.6 | 135.9 |
| Cash conversion cycle (days) | 207.5 | 182.4 | 130.9 | 133.3 | 122.4 | 109.0 | 76.2 | 97.6 | 143.6 | 217.6 |
| Receivables turnover | 1.64 | 1.69 | 2.32 | 2.68 | 2.89 | 2.34 | 2.51 | 2.72 | 2.66 | 2.25 |
| Payables turnover | 2.08 | 1.62 | 1.84 | 1.77 | 2.09 | 1.87 | 1.99 | 2.69 | 3.21 | 2.69 |
| Inventory turnover | 2.27 | 1.90 | 2.12 | 1.79 | 2.13 | 2.46 | 3.18 | 3.69 | 3.04 | 1.91 |
| Asset turnover | 0.39 | 0.41 | 0.56 | 0.63 | 0.72 | 0.60 | 0.64 | 0.73 | 0.61 | 0.39 |
| Average receivables | $144.7M | $196.9M | $200.7M | $156.7M | $113.6M | $88.5M | $68.5M | $59.0M | $50.2M | $41.7M |
| Average payables | $74.6M | $126.8M | $154.1M | $135.3M | $96.9M | $62.0M | $46.7M | $32.2M | $24.0M | $22.3M |
| Average inventory | $68.3M | $108.1M | $133.4M | $133.3M | $94.7M | $47.1M | $29.2M | $23.5M | $25.4M | $31.3M |
| Intangibles / total assets | 25.1% | 38.4% | 33.9% | 35.0% | 21.8% | 24.4% | 20.5% | 28.6% | 20.9% | 28.0% |
Computed from BIOX's annual financial statements (latest annual report filed June 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BIOX valuation and financial ratios
Bioceres Crop Solutions earned a return on equity of −152.6% and a return on invested capital of 0.0% in fiscal 2026. It ended the year with $236.8 million of debt and $12.2 million in cash and short-term investments, net debt of $224.6 million. The share count rose 126.3% from 28.1M to 63.6M over 9 years.
See the BIOX income statement, the BIOX chart for price history, or the BIOX stock overview for the latest quote and news.
BIOX key metrics FAQ
What is Bioceres Crop Solutions's return on equity?
Bioceres Crop Solutions's return on equity (ROE) was −152.6% in fiscal 2026: net income of -$230.3 million on average shareholders' equity of $151.0 million.
What is Bioceres Crop Solutions's ROIC?
Bioceres Crop Solutions's return on invested capital was 0.0% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Bioceres Crop Solutions have?
Bioceres Crop Solutions had total debt of $236.8 million at the end of fiscal 2026, a debt-to-equity ratio of 6.06.
What is Bioceres Crop Solutions's current ratio?
Bioceres Crop Solutions's current ratio was 0.81 at the end of fiscal 2026: current assets were 0.81 times current liabilities.